AKT1 and neoplasm: While this may be especially relevant for TNBC, an aggressive cancer subtype that currently lacks effective targeted therapies, we speculate that GPS2 status may be equally important in forecasting HR + tumor responsiveness to both PI3K/AKT inhibition and hormonal therapy via estrogen deprivation/anti-estrogen treatment.